LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 8th Annual Cancer Research and Oncology Virtual Event! This two day event will take place on October 7th and 8th, 2020 and will focus on advancements in prevention, diagnosis and treatment of different cancer types.
Cancer research has made major advancements in diagnosis, treatments, and the basic understanding of the disease itself. Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a strong focus on learning more about the origination of the disease.
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open 6 months from the date of the live event. The webinars will be available for unlimited on-demand viewing. This virtual conference also offers increased reach for the global microbiology community with a high degree of interaction through live-streaming video and chat sessions.
Like the 2019 conference, this event will be produced on our robust platform, allowing you to watch, learn and connect seamlessly across all desktop or mobile devices. Equipped with gamification and point system, you can now move around the entire event, earning points for a chance to win one of LabRoots' most popular T-shirts.
Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2020 Cancer Research and Oncology Virtual Event. Submission is free. Submit your abstract here.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 35 credits.
Use #LRcancer to follow the conversation!
POSTER SUBMISSION GUIDELINES
Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.
SUBMIT YOUR ABSTRACT
Enter the following information to this Submission Form:
All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.
If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.
Questions? Email Posters@LabRoots.com
I am a practicing Gynecologic Oncologist and Geneticist. I lead the Cancer Genetics Program at the Upstate Cancer Center in Syracuse, NY. In addition to this, I am actively involved in medical education and clinical research in Oncology. In my free time, I like to read books, movies, hiking and eating out.
David began his career at Miltenyi Biotec over ten years ago as a R&D laboratory technician. The ambitious student continued his education throughout his time at Miltenyi – first earning a Bachelors degree in Molecular Biology from Johannes Gutenberg University Mainz, then earning a Masters degree in the Life Sciences from HAN University of Applied Sciences in the Netherlands. Presently, David is continuing his studies as a PhD student while simultaneously remaining a valued member of Miltenyi’s R&D team, developing innovative solutions for cancer research.
Dr. Akinyemiju is an Associate Professor of Epidemiology with expertise in cancer epidemiology, cancer biology, epidemiologic methods, and health disparities. Her research interests include quantifying the impact of social (e.g. access to healthcare and structural racism) and biological factors (e.g. metabolic and inflammatory dysregulation) on racial disparities in cancer risk, tumor aggressiveness, quality of treatment and survival. This line of inquiry has resulted in over 100 publications till date. Dr. Akinyemiju is the PI of an NIH funded study examining the role of metabolic dysregulation and associated epigenetic changes in risk of aggressive, hormone-receptor negative breast cancer in women of African descent, and an R01 characterizing racial differences in various healthcare access dimensions, and how these predict poor treatment utilization and lower survival among Black, Hispanic and White ovarian cancer patients. These ultimate goal of these studies is to provide novel, empirical and generalizable insights that can help identify and prioritize specific modifiable factors that can be targeted to reduce cancer disparities and improve care for all patients, findings that will likely be beneficial across a range of cancer types where racial disparities remain an intractable problem.
Vivian Barry is a Senior Scientist in the Pathobiology group at Gilead Sciences. She began her career in molecular biology and immunology research areas at DNAX and Genentech. She eventually ventured into histopathology research and became the manager of the immunohistochemistry team at Arresto Biosciences in 2008. Vivian joined Gilead in 2011, with the acquisition of Arresto, and has been managing the IHC/Pathology group at Gilead since that time. Over the years, she has focused on building the histopathology lab and has introduced various machinery and techniques to enhance the delivery of high quality IHC and CISH data. Her team focuses on target validation in both human tissues and animal models, assists in determining mechanism of action of therapeutics and small molecules, and is involved in IND-enabling studies. She collaborates with investigators across Gilead’s departments; these projects include virology, immunology, oncology, and fibrotic diseases. Vivian received her Bachelor of Science and Master of Science degrees at the University of San Francisco, and has recently received her MBA from the Golden Gate University, San Francisco.
Ben currently leads a team of forward-thinking product and service managers within MilliporeSigma's Genome Engineering and Modulation franchise. His first exposure to CRISPR-based genome editing was as a graduate student where he attempted to engineer novel protein variants. This work inspired a passion for CRISPR technology which he has brought with him to his current role within a company that is laser-focused on developing and utilizing revolutionary genome editing technologies. Prior to joining Merck KGaA, he has worked in various commercial and technical roles at Berkeley Light Inc., Agilent Technologies, Nanopore Diagnostics, and several small start-up companies focused on software applications. Ben has a PhD in computational biology from Washington University in St. Louis.
Matthew Cooperberg graduated from Dartmouth College, where he finished summa cum laude with a major in English. He earned his MD and MPH degrees at Yale University, and completed residency in Urology and fellowship in Urologic Oncology at UCSF. At the end of his training, Dr. Cooperberg joined the faculty at UCSF. He is Chief of Urology at the San Francisco VA Medical Center, and he maintains busy clinical practices both there and at the UCSF Helen Diller Family Comprehensive Cancer Center, where is the Urology co-Leader of the Prostate Program. He also holds a secondary appointment in the Department of Epidemiology & Biostatistics. He is actively engaged in research approaching the challenges of prostate cancer from many interrelated angles, from molecular analyses to health system-wide research. He has written or contributed to over 370 research articles. Early in 2013 Dr. Cooperberg co-authored a proposal for a national urology registry which served as the basis for the AUA Quality (AQUA) Registry, a project for which he now serves as Senior Physician Advisor. In 2015 he won the AUA Gold Cystoscope Award, and in 2016 was awarded his first R01 grant as Principle Investigator from the National Cancer Institute, to develop and validate novel miRNA-based biomarker signatures for refined prostate cancer prognosis. He lives in San Francisco with his wife, Jacqueline Dolev (a derm-atologist and fellow Yale Medical School alum), where they work primarily to keep up with their children, Jake and Sarah.
Branden Hopkinson has a PhD in Cellular and Genetic Medicine from the University of Copenhagen as well as a background in human embryonic stem cells and identification of cell origin for the various types of breast cancer. He also has extensive experience in the exploration of biomarkers for cell identification and diagnostic purposes.
Dr. Özlem Karalay, Senior Scientist, Digital PCR Assay Development, QIAGEN GmbH Özlem Karalay studied Molecular Biology & Genetics at the Middle East Technical University, Turkey, and obtained her M.Sc. degree in Neuroscience from the MPI for Developmental Biology, Tübingen. She received her doctorate in Neuroscience from the Swiss Federal Institute of Technology (ETH), Zürich. She joined QIAGEN after completion of her postdoctoral research at the MPI for Biology of Ageing, Cologne, and since then has been involved in developing the digital PCR assay portfolio, including mutation detection and CNV assays.
Masahito Kawazu began his medical research after studying medicine at the University of Tokyo and being trained as a hematologist. After earning a degree in research on transcription factors and conducting research on transcriptional regulators as a postdoctoral fellow, he joined Department of Cellular Signaling, The University of Tokyo, in 2010 and started his research on genomic medicine. His research focuses on genomic abnormalities of cancer cells. He aims to find genomic abnormalities that drive the growth of cancer or that affect the immune environment of cancer. He performed a genome analysis of breast cancer and microsatellite instability-high colorectal cancer, and clarified the characteristics of their genomic abnormality. Recently, his team is trying to analyze the abnormal transcripts resulting from the structural variations (chromosomal rearrangement) of cancer genome using a long-read sequencer.
Dr. Kimbro is a biomedical scientist, educator, and community researcher. With a career-spanning nearly thirty years in a wide variety of institutions across this country, Dr. Kimbro has continued to pursue excellence in the classroom and at the bench. He currently serves as a Professor of Biological and Biomedical Science at North Carolina Central University (NCCU) where his research focus involves the innate immune response pathway in cancer development and risk in African American populations. He returned to full-time research after serving as the Director of the Julius L. Chambers Biomedical/Biotechnology Research Institute (Institute). Dr. Kimbro’s cancer disparities expertise is widely recognized as evidenced by serving as a peer-reviewer of grants for the National Institutes of Health and his multiple peer-reviewed publications in health disparities. Dr. Kimbro is passionate about developing the next generation of investigators and has consistently been regarded as a favorite among graduate and undergraduate students alike. He is deeply committed to his community and has exercised considerable leadership in the area of health disparities. Prior to joining NCCU, Dr. Kimbro served as the Program Director of the Georgia Center for Health Equality at the Emory University School of Medicine, Winship Cancer Institute, a NIH Center of Excellence (COE). In his role at the Institute, Sean was instrumental in managing a variety of programs and initiatives to identify and address health disparities, particularly in the African-American community. Dr. Kimbro holds a B.A. in Biology from Washington University in St. Louis and a Ph.D. in Biological Sciences, with an emphasis in Molecular and Microbiology from Indiana University. He completed post-doctoral positions at Harvard University Medical School and the National Institutes of Health, National Institute of Environmental Health Sciences at Research Triangle Park, North Carolina.
Dr. Ming Liu is a Senior Vice President of Shanghai ChemPartner and is the head of the Biology and Pharmacology Department. Dr. Liu has more than 25 years of experience in drug discovery and development, with a focus on pre-clinical evaluations of novel therapeutic agents. Dr. Liu obtained his Ph.D. of Molecular Virology from Baylor College of Medicine in Houston, Texas. He received his postdoctoral training at the Dana Farber Cancer Institute at Harvard Medical School in Boston, Massachusetts. He worked for Schering-Plough and Merck Pharmaceuticals for nearly 20 years, focusing on cancer drug discovery and development. Additionally, Dr. Liu is a licensed veterinarian in Taiwan and the United States. He has published 40 peer review articles, 10 patents, and 4 book chapters.
Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course. Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).
Dr. Mellert is a Senior Director within the Biodesix development group. She has a background in molecular cancer biology and experience leading teams in the development and commercialization of blood-based, and now respiratory based, diagnostic tests under CAP/CLIA and NYS CLEP. Dr. Mellert has played a leading role in the launch and on-market support of the GeneStrat tests which uses ddPCR technology. Most recently she has contributed to the expanded use of this platform at Biodesix to support molecular testing for SARS-CoV-2 infection. She continues to focus her efforts on bringing relevant and actionable genomic and proteomic information into the Clinical Laboratory to support pharmaceutical development programs and physicians. Dr. Mellert received her Ph.D from the University of Pennsylvania and post-doctoral training at the University of Colorado. She has received several honors including the American Cancer Society Post-doctoral fellowship and inaugural Biodesix Invent Our Future award.
Vipul Patel, MD, FACS completed his medical school education at Baylor College of Medicine in Houston, TX. He then completed his residency and fellowship training at the University of Miami in Florida. Subsequently, Dr. Patel served as director of the Robotic Surgery Program at The Ohio State University in Columbus, Ohio, prior to joining Advent Health Celebration. Dr. Patel is board certified by the American Urological Association and is the medical director of the Global Robotics Institute at Advent Health Celebration and medical director of the Advent Health Cancer Institute Urologic Oncology Program. He is a professor of Urology at the University of Central Florida College of Medicine in Orlando, Florida, and a clinical associate professor of Urology at Nova Southeastern University, also in Orlando. He serves as an honorary professor at the University of Milan, Korea University and Ricardo Palma University in Lima, Peru, and was recently made an honorary professor of the Russian Academy of Science. He is the founder of the International Prostate Cancer Foundation (IPCF) and a founding member of the Society of Robotic Surgery. He is the editor emeritus of The Journal of Robotic Surgery and editor of the first-ever robotic urology textbook. He leads one of the world’s most experienced robotic surgery teams and travels around the world to educate physicians and care for patients. Dr. Patel is world-renowned for his contribution to the field of robotic surgery and prostate cancer. Dr Patel is the most experienced robotic surgeon in the world and has personally performed nearly 14,000 robotic prostatectomies for the treatment of prostate cancer. Dr. Patel has developed techniques in robotic surgery that have translated to improve patient care and outcomes. His innovations have helped to improve cancer treatment and return of early urinary continence and sexual function. His contributions have been recognized worldwide through publications, professorships and training courses. He has traveled the globe lecturing and teaching. He has educated thousands of surgeons in robotic surgical techniques. He has started robotic surgery programs or performed surgery throughout the United States and in countries, including India, China, England, Sweden, Belgium, Turkey, Australia and South Korea. He currently serves as president of the Florida Urologic Society and Past president and Managing Director of the Society of Robotic Surgery.
Steven R. Patierno, PhD serves as Professor of Medicine, Professor of Pharmacology and Cancer Biology and Professor of Family Medicine and Community Health at the Duke University School Medicine, and as Deputy Director of the Duke Cancer Institute (DCI), one of the original eight NCI-designated Comprehensive Cancer Centers. He earned a Bachelor of Science in Pharmacy from the University of Connecticut, a PhD in molecular pharmacology from the Graduate School of Biomedical Science, University of Texas Health Science Center-MD Anderson Cancer Institute in Houston Texas, and conducted an NIH-awarded postdoctoral fellowship at the University of Southern California (USC) Norris Comprehensive Cancer Center in molecular oncology and carcinogenesis. He was the Vivian Gill Distinguished Professor of Oncology, and Professor of Pharmacology, Physiology and Urology at the GWU School of Medicine and Health Sciences, and served as Executive Director of The George Washington University Cancer Center for ten years prior to moving to Duke in 2012. Dr. Patierno’s basic science and translational research laboratory has been funded continuously by the NIH, NCI, Department of Defense and multiple foundations for over 25 years. He is internationally recognized for research on molecular carcinogenesis, molecular pharmacology and oncology, the genomics of cancer disparities and healthcare delivery research on patient navigation and evidence-based policy. Currently, his laboratory is focused on the molecular biology of cancer disparities including the development of biomarkers for high risk cancer and identification and development of novel molecularly targeted therapeutics. He serves on many national committees for AACR, AACI, and ASCO, and as chair of numerous scientific and medical advisory boards. He co-chaired the 2007, and keynoted the 2018 AACR-NCI Think Tanks on Cancer Disparities and help found the AACR Science of Cancer Disparities Annual Conference. Dr. Patierno received a Prostate Cancer Foundation 2018 Challenge Award, the AACR 2019 Distinguished Cancer Disparities Research Award, and has been recognized as a Distinguished Alumnus of the University of Texas MD Anderson Cancer Institute. He has also been recognized by Duke University for his extensive work in Diversity and Inclusion and by numerous organizations for impactful community engagement.
Dr. James Porter is Director of Robotic Surgery at Providence St. Joseph Health Care System and Swedish Medical Center in Seattle, Washington. He is former Associate Professor of Urology and head of laparoscopy and robotics in the Department of Urology at the University of Washington Medical Center. He performed the first laparoscopic radical prostatectomy in the Pacific Northwest on October, 2000. His area of expertise is robotic assisted prostatectomy, and partial nephrectomy. He developed the retroperitoneal approach for robotic renal surgery and pioneered retroperitoneal lymph node dissection for the treatment of testicular cancer. He has been director of a fellowship in robotic and laparoscopic surgery for the last 18 years. He is the most experienced laparoscopic and robotic surgeon in the Pacific Northwest and has performed over 4,000 robotic procedures. He earned his undergraduate degree in biochemistry at Ohio State University. He received his medical degree from the Medical College of Ohio and performed his urology residency at the University of Washington Medical Center. He obtained advanced laparoscopic training in Heilbronn, Germany under the direction of Dr. Jens Rassweiler.
Professor Rutella is a licensed haematologist and Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre. His academic career has been predicated on the bench-to-bedside-to-bench paradigm in Haematology. Over the last 25 years, Professor Rutella has been engaged in clinical and translational research focusing on immunotherapy approaches to improve the outcome of haematological malignancies, with an emphasis on antibody-based therapeutics and haematopoietic stem cell transplantation. At Nottingham Trent University, Professor Rutella’s research program focuses on visualising the state of cancer-immune interactions in individual patients and on biomarker discovery, with the aim to design rational immunotherapy approaches and to guide treatment choices.
Martin Schlumpberger is Director, Product Development at QIAGEN focusing on exosomes and circulating, cell-free nucleic acid isolation. Before his current role, he successfully led the development of various RNA isolation products at QIAGEN, including RNeasy FFPE, RNeasy Plus, AllPrep DNA/RNA, miRNeasy and QIAsymphony RNA kits. Prior to joining QIAGEN, Martin worked as a postdoctoral fellow at the Institute for Neurodegenerative Diseases at UCSF, USA. He holds a Ph.D. in chemistry, with a strong focus on molecular biology and yeast genetics, from the University of Stuttgart, Germany.
Dr. Wayne Speckmann has been working in R&D for over 20 years and is an expert in antibody development and immunoassays.
Neil Vasan is an Assistant Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. He is a physician-scientist working in the laboratory of Dr. Lewis Cantley (Weill Cornell Medical College) on oncogenic kinases and mechanisms of response to targeted therapies, with a focus on breast cancer. His work has been published in Nature and Science. He has received the NIH/NCI K08 Award, the Susan G. Komen Career Catalyst Research Award, the ASCO Young Investigator Award, and was named a 2020 AACR NextGen Star.
DNA and RNA extraction is the first step for many downstream analyses. Efficient, clean nucleic isolation is crucial. Our goal is to offer high-quality nucleic acid purification solutions to help you improve your workflows for clinical, basic research and biotechnology for cancer ...See more See less
BioLegend enables life science discovery from research to cure by providing world-class quality biological reagents and tools at an outstanding value, with highly acclaimed customer service and technical support. Guided by our award-winning entrepreneurial leadership team, we ...See more See less
ATCC is the premier global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While ...See more See less
Miltenyi Biotec delivers solutions that advance biomedical research and cellular therapy. As the SARS-CoV-2 pandemic continues to take its toll around the world, Miltenyi Biotec stands committed to helping our customers navigate through this challenging time. With over 30 years ...See more See less
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and ...See more See less
Analytik Jena is a provider of instruments and products in the areas of analytical measuring technology and life science. Its portfolio includes the most modern analytical technology and complete systems for bioanalytical applications in the life science area. Comprehensive ...See more See less
Sony Biotechnology Inc. is dedicated to helping researchers working across different life science disciplines to achieve the best scientific results. By leveraging Sony's vast know-how in electronics innovation and design we offer next-generation cell analysis systems to ...See more See less
LI-COR first introduced scientific instruments for plant science research and quickly grew to provide scientists tools for such diverse disciplines as atmospheric research and the study of how proteins interact at the cellular level. LI-COR Biosciences is a global leader in the ...See more See less
Millipore Sigma is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis ...See more See less
Luminex's mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and ...See more See less
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications ...See more See less
Envigo provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. As the largest organization that is solely dedicated to providing research models and related ...See more See less
At Atlas Antibodies we have a very clear mission: To provide our customers with advanced research reagents targeting all human proteins. The Human Protein Atlas (HPA) project released the first version of a complete tissue-based map of human protein expression using antibodies in ...See more See less
OriGene Technologies was founded as a research tool company focused on the creation of the large commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based ...See more See less
With a portfolio of more than 4,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in ...See more See less
As a global leader in healthcare, Roche Diagnostics offers a broad portfolio of tools that help healthcare providers in the early detection, prevention, diagnosis and treatment of diseases. In Molecular Diagnostics, we are driven by a vision of working with laboratories like ...See more See less
Thermo Fisher Scientific offers chemicals, reagents, and materials to enable innovation, increase productivity and improve safety. With a portfolio of over 100,000 products, we offer choice and supply assurance for your analytical, life science, organic and inorganic chemical ...See more See less
For more than 30 years, GoldBio has been committed to researchers around the world. We know providing quality reagents to scientists leads to discoveries that benefit all. That is why we provide our customers with only the best chemicals, tested in GoldBio labs to ensure the ...See more See less
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological ...See more See less
ChemPartner is a global full-service life science CRO/CDMO with over 18 years of pharmaceutical research experience, evolved from the pure chemistry service provider, focusing on research innovation with global reach. As more and more pharmas and biotech companies look for ...See more See less
Visiopharm® is a world leader in Augmented Pathology™ solutions; that comprise precision pathology and high-throughput pathology for tissue-diagnostics and research. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and ...See more See less
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
Dr. David M. Albala graduated with a geology degree from Lafayette College in Easton, Pennsylvania. He completed his medical school training at Michigan State University and went on to complete his surgical residency at the Dartmouth-Hitchcock Medical Center. Following this, Dr ...See more See less
Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...See more See less
Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been ...See more See less
Keith L. Knutson, Ph.D., is a consultant in the Department of Immunology, Mayo Clinic in Florida, where he also serves as director of the Discovery and Translation Lab's Cancer Research Program. Dr. Knutson joined the staff of Mayo Clinic in 2005 and holds the academic rank of ...See more See less
Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He ...See more See less
Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...See more See less
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events